# Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022)

> **NCT01554176** · PHASE2 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 129 (actual)

## Conditions studied

- Major Depressive Disorder, Recurrent

## Interventions

- **DRUG:** Filorexant
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01554176
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-05-18
- **Primary completion:** 2013-09-03
- **Final completion:** 2013-09-03
- **Target enrollment:** 129 (ACTUAL)
- **Why stopped:** Low Enrollment
- **Last updated:** 2018-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01554176

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01554176, "Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01554176. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*